Given this background and the fact that the apparent potency of ALT-801 for the GLP-1R is comparable to that of semaglutide (EC50 of 39 pM and 15 pM, respectively20) it is reasonable to conclude that GCGR activation is responsible for the improved activity of ALT-801 over semaglutide in this NASH model. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.